Cargando…

CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva

Introduction. The importance of human saliva in aerosol-based transmission of SARS-CoV-2 is now widely recognized. However, little is known about the efficacy of virucidal mouthwash formulations against emergent SARS-CoV-2 variants of concern and in the presence of saliva. Hypothesis. Mouthwashes co...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Enyia R., Patterson, Edward I., Richards, Siobhan, Pitol, Ana K., Edwards, Thomas, Wooding, Dominic, Buist, Kate, Green, Alison, Mukherjee, Sayandip, Hoptroff, Michael, Hughes, Grant L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Microbiology Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941951/
https://www.ncbi.nlm.nih.gov/pubmed/35180046
http://dx.doi.org/10.1099/jmm.0.001508
_version_ 1784673207466328064
author Anderson, Enyia R.
Patterson, Edward I.
Richards, Siobhan
Pitol, Ana K.
Edwards, Thomas
Wooding, Dominic
Buist, Kate
Green, Alison
Mukherjee, Sayandip
Hoptroff, Michael
Hughes, Grant L.
author_facet Anderson, Enyia R.
Patterson, Edward I.
Richards, Siobhan
Pitol, Ana K.
Edwards, Thomas
Wooding, Dominic
Buist, Kate
Green, Alison
Mukherjee, Sayandip
Hoptroff, Michael
Hughes, Grant L.
author_sort Anderson, Enyia R.
collection PubMed
description Introduction. The importance of human saliva in aerosol-based transmission of SARS-CoV-2 is now widely recognized. However, little is known about the efficacy of virucidal mouthwash formulations against emergent SARS-CoV-2 variants of concern and in the presence of saliva. Hypothesis. Mouthwashes containing virucidal actives will have similar inactivation effects against multiple SARS-CoV-2 variants of concern and will retain efficacy in the presence of human saliva. Aim. To examine in vitro efficacy of mouthwash formulations to inactivate SARS-CoV-2 variants. Methodology. Inactivation of SARS-CoV-2 variants by mouthwash formulations in the presence or absence of human saliva was assayed using ASTM International Standard E1052-20 methodology. Results. Appropriately formulated mouthwashes containing 0.07 % cetylpyridinium chloride but not 0.2 % chlorhexidine completely inactivated SARS-CoV-2 (USA-WA1/2020, Alpha, Beta, Gamma, Delta) up to the limit of detection in suspension assays. Tests using USA-WA1/2020 indicates that efficacy is maintained in the presence of human saliva. Conclusions. Together these data suggest cetylpyridinium chloride-based mouthwashes are effective at inactivating SARS-CoV-2 variants. This indicates potential to reduce viral load in the oral cavity and mitigate transmission via salivary aerosols.
format Online
Article
Text
id pubmed-8941951
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Microbiology Society
record_format MEDLINE/PubMed
spelling pubmed-89419512022-03-29 CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva Anderson, Enyia R. Patterson, Edward I. Richards, Siobhan Pitol, Ana K. Edwards, Thomas Wooding, Dominic Buist, Kate Green, Alison Mukherjee, Sayandip Hoptroff, Michael Hughes, Grant L. J Med Microbiol Prevention, Therapy and Therapeutics Introduction. The importance of human saliva in aerosol-based transmission of SARS-CoV-2 is now widely recognized. However, little is known about the efficacy of virucidal mouthwash formulations against emergent SARS-CoV-2 variants of concern and in the presence of saliva. Hypothesis. Mouthwashes containing virucidal actives will have similar inactivation effects against multiple SARS-CoV-2 variants of concern and will retain efficacy in the presence of human saliva. Aim. To examine in vitro efficacy of mouthwash formulations to inactivate SARS-CoV-2 variants. Methodology. Inactivation of SARS-CoV-2 variants by mouthwash formulations in the presence or absence of human saliva was assayed using ASTM International Standard E1052-20 methodology. Results. Appropriately formulated mouthwashes containing 0.07 % cetylpyridinium chloride but not 0.2 % chlorhexidine completely inactivated SARS-CoV-2 (USA-WA1/2020, Alpha, Beta, Gamma, Delta) up to the limit of detection in suspension assays. Tests using USA-WA1/2020 indicates that efficacy is maintained in the presence of human saliva. Conclusions. Together these data suggest cetylpyridinium chloride-based mouthwashes are effective at inactivating SARS-CoV-2 variants. This indicates potential to reduce viral load in the oral cavity and mitigate transmission via salivary aerosols. Microbiology Society 2022-02-18 /pmc/articles/PMC8941951/ /pubmed/35180046 http://dx.doi.org/10.1099/jmm.0.001508 Text en © 2022 Unilever https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License. The Microbiology Society waived the open access fees for this article.
spellingShingle Prevention, Therapy and Therapeutics
Anderson, Enyia R.
Patterson, Edward I.
Richards, Siobhan
Pitol, Ana K.
Edwards, Thomas
Wooding, Dominic
Buist, Kate
Green, Alison
Mukherjee, Sayandip
Hoptroff, Michael
Hughes, Grant L.
CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva
title CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva
title_full CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva
title_fullStr CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva
title_full_unstemmed CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva
title_short CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva
title_sort cpc-containing oral rinses inactivate sars-cov-2 variants and are active in the presence of human saliva
topic Prevention, Therapy and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941951/
https://www.ncbi.nlm.nih.gov/pubmed/35180046
http://dx.doi.org/10.1099/jmm.0.001508
work_keys_str_mv AT andersonenyiar cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva
AT pattersonedwardi cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva
AT richardssiobhan cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva
AT pitolanak cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva
AT edwardsthomas cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva
AT woodingdominic cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva
AT buistkate cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva
AT greenalison cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva
AT mukherjeesayandip cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva
AT hoptroffmichael cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva
AT hughesgrantl cpccontainingoralrinsesinactivatesarscov2variantsandareactiveinthepresenceofhumansaliva